|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Osler Chest Unit (Dr. Ho), Churchill Hospital, Oxford; and The Respiratory Unit (Drs. Denison, Wood, and Greening, and Ms. Davis), Western General Hospital, Edinburgh, UK.
Correspondence to: Ling-Pei Ho, MD, Osler Chest Unit, Churchill Hospital, Oxford OX3 7LJ, United Kingdom; e-mail: Ling-Pei.Ho{at}imm.ox.ac.uk
Study objectives: To investigate whether differing airway interleukin (IL)-18 levels may be implicated in the pathogenesis of asthma and sarcoidosis.
Setting: University teaching hospital.
Patients and methods: IL-18 levels were measured in BAL fluid and in the supernatant of lipopolysaccharide (LPS)-stimulated alveolar macrophages obtained by BAL from 15 patients with sarcoidosis, 11 patients with asthma, and 13 healthy subjects. We also examined the relationship between IL-18 levels and macrophage and lymphocyte concentrations in BAL fluid. IL-18 was measured using an in-house enzyme-linked immunosorbent assay.
Results: IL-18 levels were significantly lower in BAL fluid from patients with asthma (median, 0.0 pg/mL; interquartile range, 0.0 to 0.0 pg/mL) compared to patients with sarcoidosis (median, 222.0 pg/106; interquartile range, 110 to 340 pg/mL; p = 0.009, Mann Whitney rank-sum test) and healthy control subjects (median, 162 pg/mL; interquartile range, 38 to 203 pg/mL; p = 0.025, Mann Whitney rank-sum test). Individual analyses comparing IL-18 levels with BAL macrophage counts, and IL-18 with lymphocyte counts in the three groups showed no correlation between these indexes. The mean levels of IL-18 in unstimulated macrophage supernatants were 410 pg/106 cells for patients with asthma, 723.4 pg/106 cells for patients with sarcoidosis, and 734.8 pg/106 cells for healthy control subjects (p > 0.05). Stimulated macrophages from patients with sarcoidosis responded with increasing amounts of IL-18 at lower doses of LPS than macrophages from healthy control subjects or patients with asthma.
Conclusion: Our findings suggest that inherently low levels of IL-18 may be associated with the pathogenesis of asthmatic airway inflammation.
Key Words: asthma BAL interleukin-18 macrophage stimulation sarcoidosis T-helper type 1/T-helper type 2 lymphocytes
This article has been cited by other articles:
![]() |
K. S. Lee, S. R. Kim, S. J. Park, K. H. Min, K. Y. Lee, S. M. Jin, W. H. Yoo, and Y. C. Lee Antioxidant Down-Regulates Interleukin-18 Expression in Asthma Mol. Pharmacol., October 1, 2006; 70(4): 1184 - 1193. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-Z. Wang, Y.-X. Bao, C. L. Rosenberger, Y. Tesfaigzi, J. M. Stark, and K. S. Harrod IL-12p40 and IL-18 Modulate Inflammatory and Immune Responses to Respiratory Syncytial Virus Infection J. Immunol., September 15, 2004; 173(6): 4040 - 4049. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peters-Golden The Alveolar Macrophage: The Forgotten Cell in Asthma Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 3 - 7. [Full Text] [PDF] |
||||
![]() |
W. A. Colburn Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing J. Clin. Pharmacol., April 1, 2003; 43(4): 329 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Gracie, S. E. Robertson, and I. B. McInnes Interleukin-18 J. Leukoc. Biol., February 1, 2003; 73(2): 213 - 224. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |